White Paper

Specialty Drugs in Workers’ Compensation Update A Population-Based Assessment (2020 Update)

Specialty medicines are rapidly approaching half of total drug spend. Across all settings, specialty medicines treat relatively few patients and have costs far higher per patient than traditional medicines.

White Paper Summary

Specialty drugs are typically newer, complex, high-value medications that are rapidly becoming standard treatment for many rare and chronic conditions. According to Information Medical Statistics (IMS) Health, United States specialty net spending rose from 24.7% in 2008 to 46.5% in 2017.

In this paper, myMatrixx will identify the significant patient populations where specialty drugs are the treatment of choice, including injured workers who have undergone orthopedic surgery, workers who have been exposed to HIV or hepatitis C, patients with conditions such as ankylosing spondylitis and rheumatoid arthritis as well as other key groups. Since these treatments also require enhanced clinical monitoring and medication management to ensure successful outcomes, this report will also cover the important role that pharmacy benefits managers play in this process.

Register to download the full content

To learn more about myMatrixx, please visit their website.

myMatrixx® is a pharmacy benefit management company dedicated to workers’ compensation. The unique combination of myMatrixx and Express Scripts makes us the only workers’ compensation pharmacy benefit manager that can deliver high touch customer service, clinical expertise and actionable data analytics while leveraging Express Scripts’ pharmacy network, comprehensive clinical services, mail order program and specialty solutions to meet the individual needs of our clients and their injured workers. For more information, visit myMatrixx.com.

More from Risk & Insurance

More from Risk & Insurance

Risk Matrix: Presented by Liberty Mutual Insurance

10 Severe Weather Risks Affecting Businesses’ Property and More

Every year, severe weather costs approximately $630 billion for the U.S. But this is not a property issue alone; several lines are feeling the strain.
By: | June 1, 2021

The R&I Editorial Team can be reached at [email protected]